STOK
Stoke Therapeutics, Inc.
Next earnings Aug 10, 2026 · consensus $-0.81 EPS, $6.28M rev
Last earnings -1.5% on 2026-05-07
$30.40
▲ +0.03%$30.40▲ +162.52%
over 1Y
L $11.35EODHDH $38.35
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+0.0%
1W-1.9%
1M-2.0%
3M-9.8%
YTD-1.6%
1Y+162.5%
Hold
Conviction
Horizon
Medium (3–12mo)
Street · 18 analysts
Strong Buy
Revenue grew 404.5% YoY; but unprofitable (net margin -3.7%).
Stoke Therapeutics, Inc. shows $184M in FY2025 revenue (+404.5% YoY), a -3.7% net margin, and -2.0% ROE.
Sources: SEC EDGAR (CIK 0001623526, latest 10-Q filed 2026-05-07) · EODHD · as of 6/26/2026, 12:43:26 AM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.